A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Key facts

Sponsor

Arcturus Therapeutics, Inc.

Intervention

ARCT-810(biological)

Enrollment

9 enrolled

Eligibility

12 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Uncommon Cures, Chevy Chase, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ornithine transcarbamylase deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06805695
  Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
  iECURE, Inc.
• RECRUITINGPHASE1, PHASE2NCT06255782
  An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
  iECURE, Inc.
• RECRUITINGPHASE1, PHASE2NCT05092685
  Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
  University College, London
• ACTIVE NOT RECRUITINGPHASE3NCT05345171
  Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
  Ultragenyx Pharmaceutical Inc
• RECRUITINGNCT04908319
  Hepatic Histopathology in Urea Cycle Disorders
  Baylor College of Medicine
• ACTIVE NOT RECRUITINGNCT04612764
  Liver Disease in Urea Cycle Disorders
  Baylor College of Medicine
• ACTIVE NOT RECRUITINGNCT03636438
  Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
  Ultragenyx Pharmaceutical Inc

See all trials for Ornithine transcarbamylase deficiency →